ClinicalTrials.gg
Active, not recruitingNCT04943926CARBCOUNTUpdated Oct 2, 2026

Dietary Strategies for Remission of Type 2 Diabetes

An interventional study of Energy restricted diet and Low carbohydrate high fat diet in Diabetes Mellitus, Type 2, Overweight and Obesity and Hypertension, sponsored by University of Bergen. Active, not recruiting at 1 site in Norway. Open to participants aged 24 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Bergen · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
24 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Norway.

Planned enrollment
43rd of 103
600 · median 503
Started
2022
with 1 other
No phase
24 of 116
2 open now
Registered
111th of 116
by date

Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, this one is the 43rd largest by planned enrollment of the 103 interventional ones that give a count, is one of 2 that started in 2022, is one of 24 with no phase, and was the 111th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 24 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, or all of them as a file.
02

Study summary

In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program) can produce and maintain equal remission rates of type 2 diabetes (T2D) as a nutritionally complete very-low-calorie formula diet followed by a energy-restrictive (i.e., calorie counting) diet (DiRECT principles). Within the principles of each approach, the dietary goals and change will be adjusted according to individual needs/capabilities conducive to long-term adherence. Furthermore, the investigators aim to determine whether the rate of diet-induced remission is reflected in/can be predicted by baseline or diet-induced changes in glucose variability (e.g., time-in-range measured by continuous glucose monitoring) and other factors such as anthropometric changes and genetic susceptibility. Each center will also conduct locally-lead standalone mechanistic research, including analyses of intra-abdominal/hepatic fat accumulation, adipose tissue biopsies and/or measurements of energy metabolism. Additionally, changes in medication use, nutritional status, cardiovascular disease risk, as well as adverse events, will be monitored.

Read the detailed description

At least 588 patients with T2D will be recruited, approximately 120-150 men and women at each research center. The participants will be randomised to 1) a nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months or 2) a very low-carbohydrate high-fat (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months. Each of the diets will cover all basic requirements for essential nutrients including amino acids, fatty acids, vitamins and minerals. Participants will be encouraged to consume at least 200 g of vegetables per day. Furthermore, we will emphasize high-quality, minimally processed foods. In arm 2 they will receive advice to eat specific fat sources such as extra virgin olive oil, butter and high-fat cheeses.

The DiRECT trial showed remission in 46% of participants after 12 months. Assuming that both the DiRECT program and LCHF dietary strategies yield a 45% chance of T2D remission after 15 months, it is calculated (using nQuery v8) that each group needs 235 participants to complete the trial. This sample size yields 90% statistical power to conclude, with respect to the primary outcome, whether the CarbCount Program is no more than 15% more or less effective than the DiRECT principles (equivalence study, one-sided p-value at 0.025). To allow for expected loss to follow-up (estimated at 20%), each of the arms needs at least 294 participants for a total of 588.

Participants will have access to electronic platforms that include an online database of recipes (breakfast, easy-to-cook lunches, snacks, dinners, and food for special occasions). The platforms will facilitate planning of week menus, and include an e-learning course covering topics such as how to cook and prepare foods, meal planning, dining out, sleep and individual aspects that challenge habit change. If the participants are failing in their efforts to establish or maintain lifestyle change, they will be encouraged to seek possible solutions in the e-learning courses or to contact one of the study's health educators and/or dietitians. Specific rescue plans involving direct contact with study staff will be implemented if a participant regains more than 2 kg or experiences T2D relapse.

After individual assessment by a doctor, the participants will be taken off diabetes medication upon starting the diet, and be asked to self-monitor blood sugar changes during the first 2 weeks on the diet, followed by a consultation that includes evaluation of these changes. The need of reintroduction of medication will be done in consultation with the study doctor at least every 3 months.

Between visits, the participants will complete dietary assessments and an e-learning course, and at least once a month have follow-ups with dietitians/health educators and/or online group workshops.

The study will enroll eligible participants to the study continuously, until the total number of participants needed for the study is reached. Each participant will follow their own timeline, and attend visits at the study center at baseline, 3, 9 and 15 months.

During 2 weeks before each visit, participants will wear a continuous glucose monitor (CGM) and record food intake for at least 3 consecutive days during this period.

Measurements during visits will include anthropometric variables/body composition and energy expenditure, blood, saliva, urine and stool samples will be collected, and participants will be asked to fill out questionnaires on physical activity, sleep pattern, meal frequency, quality of life, problem areas in diabetes, eating efficacy and eating behaviors. They will also have a consultation with a registered dietitian and meet with the study medical doctor when needed.

A blinded statistician will perform the statistical analyses for the primary outcome of the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Overweight and Obesity
  • Hypertension
  • Glucose Intolerance
  • Insulin Resistance
  • Dyslipidemia Associated With Type II Diabetes Mellitus

Keywords

  • Low-carbohydrate high-fat diet
  • Energy restricted diet
  • Lifestyle change
  • Ketogenic diet
  • Total meal replacement
04

Who can participate

Ages eligible
24 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥48 mmol/mol (with or without medical treatment)
  • Less than 10 years since the diagnosis of T2D
  • ≥27 kg/m2 (≥25 kg/m2 for Asians)

Exclusion criteria

Exclusion Criteria:

  • Treatment with insulin >25 IU
  • concentration of 12% or more (≥108 mmol/mol)
  • Insulin to C-peptide ratio \<0.8 (indicative of insulin deficiency)
  • Myocardial infarction within the previous 6 months, and severe or unstable heart failure or other severe diseases including cancer, psychiatric/eating disorders, severe depression and substance abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    Energy Restricted Diet

    A nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months.

    Other: Energy restricted diet

  • Experimental
    Continuous LCHF Diet

    A very low-carbohydrate high-fat ketogenic diet (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months.

    Other: Low carbohydrate high fat diet

Interventions

  • OtherEnergy restricted diet

    Nutritional complete formula diet followed by an energy restricted diet

  • OtherLow carbohydrate high fat diet

    Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)

06

What researchers measure

Primary outcomes

  1. Diabetes remission

    Number of patients with diabetes remission, defined as no use of glucose-lowering drugs and HbA1c \<48 mmol/mol (\<6.5%) at 15 months

    Time frame: 15 months

Secondary outcomes

  1. Diabetes remission without anti-diabetes medications

    Number of patients with HbA1c \<48 and \<42 mmol/mol at 3, 9 and 15 months, both on and off anti-diabetes medication (metformin etc.)

    Time frame: 3, 9 and 15 months

  2. Changes in HbA1c and fasting glucose concentrations from baseline

    HbA1c and fasting glucose concentrations (treatment targets in current clinical practice) measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  3. Changes in fasting insulin and insulin C-peptide concentrations from baseline

    Insulin and insulin C-peptide measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  4. Changes in estimated insulin resistance and beta cell function from baseline

    The HOMA2-calculator (https://www.dtu.ox.ac.uk/homacalculator/download.php) is used to estimate insulin resistance and beta cell function based on fasting glucose and C-peptide concentrations

    Time frame: 3, 9 and 15 months

  5. Changes from baseline in the frequency of diabetes- and antihypertensive medication usage

    The number of diabetes- and antihypertensive medications used/reintroduced by each study visit counted and compared between groups

    Time frame: 3, 9 and 15 months

  6. Changes in eating behaviour from baseline and throughout the study

    Eating behaviour measured by the The Weight Efficacy Lifestyle Questionnaire - Short form (WEL-SF). The questionnaire contains 8 items on a 10-point response scale (ranging from not at all confident/very confident). Responses to each item are given a score between 0-10, summed together and transformed to percentages. Changes in these scores will be compared between the study groups for the respective time-points throughout the intervention.

    Time frame: 3, 9 and 15 months

  7. Changes in eating self-efficacy (Three-Factor Eating Questionnaire, TFEQ)

    Eating self-efficacy assessed by the Three-Factor Eating Questionnaire (TFEQ), which measures 3 aspects of eating behaviour: cognitive restraint, uncontrolled eating, and emotional eating. The questionnaire consists of 18 items on a 4-point response scale ( ranging from definitely true/mostly true/mostly false/definitely false). Responses to each item are given a score between 1 and 4 and and total scores are summed by the 3 measured aspects mentioned above. The raw scale scores are transformed to a 0-100 scale. Changes in these scores will be compared between the study groups for the respective time-points throughout the intervention.

    Time frame: 3, 9 and 15 months

  8. Changes in quality of life

    Quality of life measured by the EQ-5D-5L questionnaire, which includes 5 dimensions: mobility, self-care, usual activities, pain /discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The levels are scored with a 1-digit number and the digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. We will compare change at all timepoints between groups using both the 1-digit and the 5-digit number. The questionnaire includes the patient's self-rated health on a Visual analog scale (VAS) ranging from 0-100. The endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The scale will be transposed into percentages and the percent change will be compared between the study groups.

    Time frame: 3, 9 and 15 months

Other outcomes

  1. Rates of T2D remission dependent on polygenic risk scores for T2D

    Polygenic risk scores are calculated based on the latest GWAS data for T2D, and rates of remission compared between patients with the top 20% high- and top 20% low scores, for all participants combined and the respective diets separately

    Time frame: 3, 9 and 15 months

  2. Changes in ectopic fat accumulation from baseline

    Body fat measured by MRI (abdominal adipose tissue distribution, hepatic-, intramuscular-, pericardial- and pancreatic fat)

    Time frame: 3, 9 and 15 months

  3. Changes in liver fibrosis and steatosis from baseline

    Liver fibrosis and steatosis measured by ultrasound-based transient elastography

    Time frame: 3, 9 and 15 months

  4. Changes in markers of liver function from baseline

    Alanine transaminase (ALT), C-reactive protein (CRP) and other markers of liver function measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  5. Changes in inflammatory markers from baseline

    Circulating concentrations of selected markers of inflammation measured in fasting blood samples by ELISA

    Time frame: 3, 9 and 15 months

  6. Changes in blood pressure and pulse from baseline

    Blood pressure and pulse measured after 10 minutes in resting position

    Time frame: 3, 9 and 15 months

  7. Change in CVD risk (NORRISK) from baseline

    NORRISK calculated by the most current NORRISK calculator (https://hjerterisiko.helsedirektoratet.no/)

    Time frame: 3, 9 and 15 months

  8. Changes in total-, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and very-low-density (VLDL) cholesterol concentrations from baseline

    Blood lipids measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  9. Changes in triacylglycerols (TGs) and TG/HDL-C ratio from baseline

    Blood lipids measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  10. Changes in lipoprotein subfractions from baseline

    Lipoprotein particle numbers and sizes (small/medium/large LDL, IDL, HDL, VLDL) measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  11. Changes in apolipoproteins from baseline

    Apolipoproteins (including apoB, apoAs, ApoCs) measured in fasting blood samples

    Time frame: 3, 9 and 15 months

  12. Changes in micronutrient status from baseline

    Micronutrients measured in the circulation in fasting blood samples

    Time frame: 3, 9 and 15 months

  13. Changes in gut and oral microbiota from baseline

    Gut and oral microbiota measured by 16S sequencing in feces and saliva, respectively

    Time frame: 3, 9 and 15 months

  14. Changes in appetite/satiety and ketones from baseline

    Ghrelin and ketones measured in fasting blood samples, and correlations in the change of ghrelin and ketones (beta-hydroxybutyrate and acetoacetate) from baseline.

    Time frame: 3, 9 and 15 months

07

Study locations

1 site
  • Department of Clinical Science
    Bergen, Vestland 5021, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Sep 2026, 56 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 56 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2024 → Sep 2026 and completion Dec 2040 → Jun 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jun 29, 2021
StartActual
Jan 4, 2022
Primary completionActual
Sep 10, 2026was Dec 2024
CompletionEst.
Jun 11, 2030was Dec 2040
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Primary completion
Dec 31, 2024→Sep 10, 2026 (actual)
Oct 2, 2026
Study completion
Dec 31, 2040→Jun 11, 2030
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 31, 2024→Sep 10, 2026 (now actual)
    Study completion Dec 31, 2040→Jun 11, 2030
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04943926
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
Jan 4, 2022
Primary completion
Sep 10, 2026
Completion
Jun 11, 2030 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion